MBRX stock forecast
Our latest prediction for Moleculin Biotech, Inc.'s stock price was made on the Aug. 16, 2017 when the stock price was at 2.65$.
In the short term (2weeks), MBRX's stock price should underperform the market by -1.38%. During that period the price should oscillate between -12.37% and +22.70%.
In the medium term (3months), MBRX's stock price should outperform the market by 0.53%. During that period the price should oscillate between -25.33% and +61.34%.Get email alerts
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.52$ per share.
The book value per share is 0.62$
Three months stock forecastAug. 16, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|